Search

Displaying results 2771 - 2780 of 10000 in total
  1. Drug

    Pamrevlumab

    go.drugbank.com/drugs/DB14952
    Investigational

    Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

  2. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. … PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.

  3. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    [L54638] Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR). … [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  4. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  5. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). … [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  6. Drug

    Zilovertamab vedotin

    go.drugbank.com/drugs/DB18457
    Investigational

    mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin. … Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (

  7. Drug

    PX-12

    go.drugbank.com/drugs/DB05448
    Investigational

    PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits … Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-Methylpropyl-2-imidazolyl disulfide
  8. Drug

    TCB-008

    go.drugbank.com/drugs/DB18352
    Investigational

    TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.

  9. Drug

    AMG-553

    go.drugbank.com/drugs/DB18346
    Investigational

    AMG-553 is an adoptive, anti-FLT3 chimeric antigen receptor T-cell therapy generated through transduction of autologous T-cells with a self-inactivating human immunodeficiency virus-1 based lentiviral

  10. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine